5-Amino-1MQ
A small-molecule NNMT inhibitor (not a peptide) studied in cell and animal research; no human trials and no approval anywhere.
What it is
5-Amino-1MQ is not a peptide at all — it's a small-molecule inhibitor of NNMT, an enzyme that influences cellular energy balance. It appears in this library because peptide-market catalogs sell it alongside everything else, usually as a 'fat loss' capsule or injection.
Its entire evidence base is cell and rodent research, where NNMT inhibition increased fat-cell energy expenditure and reduced diet-induced obesity in mice. No human study of any kind has been published.
What researchers have actually studied it for
Fat-cell metabolism and diet-induced obesity — in mice and cell culture only.
How it works
It blocks nicotinamide N-methyltransferase (NNMT), an enzyme abundant in fat tissue that consumes methyl groups and influences NAD+-adjacent metabolism. Inhibit NNMT in a mouse and its fat cells burn more energy — an elegant finding awaiting any human confirmation.
The molecule itself
A small-molecule quinolinium salt — not remotely a peptide — designed as a brain-penetrant-avoiding NNMT inhibitor. NNMT sits at a metabolic crossroads, consuming methyl groups and nicotinamide (NAD+ precursor chemistry), which links it loosely to the NAD+ story one aisle over.
Where it came from
NNMT emerged as an obesity target from academic metabolism research in the 2010s, with 5-amino-1-methylquinolinium appearing in a series of rodent papers as the tool inhibitor. It jumped from lab-reagent catalogs to wellness marketing with unusual speed and zero clinical development in between.
The timeline
2010s
NNMT emerges as an obesity target in academic metabolism research.
2018+
5-amino-1MQ rodent studies report fat-mass reduction.
2020s
Wellness-market adoption with zero human data.
What the research record actually contains
- Rodent studies: reduced fat mass and improved metabolic markers with NNMT inhibition.
- Cell-culture work on fat-cell energy metabolism.
- No published human research — none.
What could change this assessment
NNMT inhibition remains academically interesting for metabolic disease; if a pharma program ever forms, it will use characterized molecules under trials — a future unrelated to today's capsules.
What's known about risks
Completely uncharacterized in humans. NNMT sits at a busy metabolic intersection (methylation and NAD+ pathways), which makes 'no human data' a heavier caveat than usual.
Where it stands legally
No approval anywhere; sold through research-chemical and supplement-gray channels.
Worth asking a licensed provider
- 1.Am I clear this is a lab compound with zero human studies?
- 2.If fat loss is the goal, why not the approved options with actual trial evidence?
- 3.What in my labs would even suggest a metabolic-enzyme experiment makes sense?
Common claims, corrected
“It's a peptide fat-burner.”
Reality: It's a small-molecule enzyme inhibitor sold through peptide channels — and 'fat-burner' summarizes mouse data only.
“Oral availability makes it consumer-ready.”
Reality: Convenient dosing of an unstudied compound is convenience only; the human file is empty regardless of format.
5-Amino-1MQ FAQ
Is 5-Amino-1MQ a peptide?
No — it's a small-molecule enzyme inhibitor sold through peptide-market channels. The chemistry matters less than the evidence tier, which is animal-only either way.
Does 5-Amino-1MQ work for weight loss?
In mice, NNMT inhibition reduced fat mass. No human study exists, so every weight-loss claim you've seen is rodent extrapolation.
Is 5-Amino-1MQ safe?
Unknown — there is no human safety data at all, and it acts on a metabolically busy enzyme. That combination deserves real caution.
What does NNMT actually do?
It methylates nicotinamide, influencing both methyl-group economy and NAD+ precursor availability — a genuine metabolic hub, which is exactly why casually inhibiting it deserves more than mouse data.
Are there human 5-amino-1MQ studies underway?
None registered — a ninety-second ClinicalTrials.gov check confirms the file is entirely preclinical.